ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

JAYANTHI GANESAN M.D.

16901 LAKESIDE HILLS CT ATTN: HOSPITAL MEDICINE

Omaha | Nebraska | 68130

(402) 398-6255

Incorrect Info?
Search this name in Dollars for Docs »
See this provider's services »

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,275Medicare Part D Prescriptions Filled, Including Refills

Rank: 87 out of 198

$480K Total Retail Price of All Prescriptions

Rank: 66 out of 198

117 Patients Receiving at Least One Drug in Part D
67%Patients 65 Years and Older
99% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

25% of this provider’s 117 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

1% of this provider’s 4,708 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$66 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

62 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
LEVOTHYROXINE SODIUM 249 177 1 1
OMEPRAZOLE 221 133 2 3
QUETIAPINE FUMARATE 219 131 3 76
FUROSEMIDE 186 148 4 5
METOPROLOL TARTRATE 184 132 5 10
RISPERIDONE 177 111 6 82
GABAPENTIN 146 87 7 14
DIVALPROEX SODIUM 146 65 7 122
AMLODIPINE BESYLATE 135 89 9 4
POTASSIUM CHLORIDE 133 115 10 9
LISINOPRIL 117 56 11 6
METFORMIN HCL 117 63 11 13
SIMVASTATIN 113 81 13 2
LANTUS 101 60 14 46
SERTRALINE HCL 100 49 15 25
GLIPIZIDE 100 42 15 62
MIRTAZAPINE 98 76 17 44
WARFARIN SODIUM 96 56 18 7
CITALOPRAM HBR 95 61 19 20
DONEPEZIL HCL 95 56 19 28
ABILIFY 94 34 21 177
HALOPERIDOL 94 61 21 210
RANITIDINE HCL 91 56 23 54
OLANZAPINE 87 77 24 162
DIVALPROEX SODIUM ER 87 36 24 186
IBUPROFEN 87 48 24 124
FENOFIBRATE 85 61 27 61
TAMSULOSIN HCL 84 47 28 27
TRAMADOL HCL 80 67 29 15
ATORVASTATIN CALCIUM 79 65 30 12
ALENDRONATE SODIUM 78 71 31 21
CLOZAPINE 65 17 32 255
HUMALOG 65 39 32 128
TRAZODONE HCL 63 61 34 50
BUSPIRONE HCL 62 48 35 132
KLOR-CON M20 60 44 36 137
HYDROCHLOROTHIAZIDE 59 16 37 16
ENALAPRIL MALEATE 58 34 38 51
OXYCODONE-ACETAMINOPHEN 57 26 S2 39 79
ESCITALOPRAM OXALATE 56 38 40 53
SPIRIVA 52 52 41 63
METHADONE HCL 52 37 S2 41 229
SEROQUEL 52 35 41 168
POLYETHYLENE GLYCOL 3350 51 31 44 41
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 7, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.